Latest
industry research report on: Diabetes Mellitus Therapeutics in
South-East Asia Market | Industry Size, Share, Research, Reviews,
Analysis, Strategies, Demand, Growth, Segmentation, Parameters,
Forecasts
Diabetes mellitus
is a group of metabolic diseases characterized by chronic hyperglycemia
- high blood glucose levels - that results from defects in insulin
secretion, insulin action, or a combination of these. This chronic
hyperglycemia is associated with long-term damage, dysfunction and
failure of multiple organs, including the eyes, kidneys, nerves, heart
and blood vessels. The vast majority of diabetes mellitus patients can
be classified as having either Type 1 Diabetes Mellitus (T1DM) or Type 2
Diabetes Mellitus (T2DM). Approximately 90-95% of all diabetics have
T2DM.
T2DM
treatment has been revolutionized in the past decade, especially with
the increased use of new therapies. The marketed products landscape
comprises a wide range of treatment options, including biguanide
(metformin), sulfonylureas, thiazolidinediones, GLP-1 receptor agonists,
DPP-4 inhibitors, SGLT-2 inhibitors, and insulin therapies.
Nevertheless, significant unmet need remains for products that can offer
better glycemic control, as well as the prevention and cure of diabetic
complications, such as diabetic nephropathy, retinopathy, and
cardiovascular disease.
Sample copy of this Report @http://www.marketresearchreports.biz/sample/sample/811828
Scope
The
current South-East Asia T2DM market contains novel products, including
Jardiance, a SGLT-2 inhibitor; Victoza, a GLP-1 receptor agonist; and
Januvia, a DPP-4 inhibitor.
- What are the competitive advantages of the existing novel drugs?
With
over 500 active pipeline molecules, most of the late-stage
investigational drug candidates are being evaluated, featuring improved
dosing regimens and administration routes in comparison to currently
marketed products and combination therapies.
- Which classes of novel drugs are most prominent within the pipeline?
- Is there strong potential for the pipeline to address unmet needs within the T2DM market?
Analysis
of clinical trials since 2006 identified that the failure rates of T2DM
molecules were highest in Phase III, at 49%, with the overall attrition
rate for T2DM standing at 75%.
- How do failure rates vary by product stage of development, molecule type, and mechanism of action?
- How do other factors, such as average trial duration and trial size, influence the costs and risks associated with product development?
Over
the 2015-2022 forecast period, the South-East Asia T2DM therapeutics
market is expected to increase in value at a CAGR of 7.1%, from $1.7
billion to over $2.7 billion.
- Which markets make the most significant contribution to the current market size?
- What are the epidemiology trends in these markets?
- Will new market entrants lead to substantial changes in annual therapy costs?
- How will different treatment usage patterns impact growth in the eight assessed South-East Asia markets?
Rising
T2DM prevalence and the uptake of newer therapies will lead to
significant market growth over the forecast period, despite generic
sales erosion resulting from patent expirations.
- Will patent expirations or emerging pipeline molecules threaten the commercial success of existing drugs?
Reasons to buy
This report will enable you to -
- Understand the clinical context of T2DM by considering symptoms, etiology, pathophysiology, epidemiology, diagnosis, and treatment options.
- Identify the therapeutic strategies, products, and companies that dominate the current marketed products landscape and recognize gaps and areas of unmet need.
- Identify key pipeline trends in molecule type, administration route, mechanism of action, and novelty.
- Consider market opportunities and potential risks by examining trends in T2DM clinical trial size, duration, and failure rate by stage of development, molecule type, and mechanism of action.
- Recognize the late-stage pipeline molecules that have demonstrated strong therapeutic potential in T2DM by examining clinical trial data and multi-scenario product forecast projections.
- Compare treatment usage patterns, annual therapy costs, and market growth projections for South Korea, Singapore, Taiwan, Malaysia, the Philippines, Thailand, Vietnam, and Indonesia.
- Discover trends in licensing and co-development deals concerning T2DM products and identify the major strategic consolidations that have shaped the commercial landscape.
About us
MarketResearchReports.biz
is the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save time
and money for our clients. We are a one stop solution for all your
research needs, our main offerings are syndicated research reports,
custom research, subscription access and consulting services. We serve
all sizes and types of companies spanning across various industries.
Contact
Mr. Nachiket
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-621-2074
No comments:
Post a Comment